ABO 2013
Alternative Names: ABO-2013Latest Information Update: 27 Jun 2025
At a glance
- Originator Suzhou Abogen Biosciences
- Class Antineoplastics; Cancer vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 27 Jun 2025 ABO 2013 is available for licensing as of 27 Jun 2025. https://www.abogenbio.com/
- 25 Apr 2025 Efficacy and adverse events data from a phase I trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)